This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
According to the World Health Organisation (WHO), an estimated two billion people across the world do not have access to essential medicines for life threatening diseases like cancer, AIDS and even autoimmune diseases like Type 1 diabetes.
Andrew Witty took the helm of pharmaceutical giant GlaxoSmithKline in May 2008. PT: Given recent problems with a safety scare over diabetesdrug Avandia and GSK’s guidance for a fall in 2008 earnings, what do you envisage Witty’s top or first priorities will be in the new job?
Obesity, metabolic syndrome, diabetes epidemic is global, so that aggravates cardiovascular risk… we are seeing a marked acceleration of heart disease deaths, and we need to find new therapies to make a difference. What are the top three trends impacting the cardiovascular drugdevelopment space today?
Shots: Immutable capital demands and high-spending drugdevelopment plans are the most common drivers in encouraging fully-fledged private healthcare companies to go public. Founded Year: 2008 No. It has also been granted RPD and FTD designation in the US and has obtained Orphan Drug Designation in both US and Europe.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content